Mihai Rusu

Mihai Rusu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PNPantelie Nicolcescu
Pantelie Nicolcescu
MMMaria Filoftea Mercut
Maria Filoftea Mercut
IMIonela Mihai
Ionela Mihai
MRMihai Rusu
Mihai Rusu
AHAdrian Gheorghe Hasegan
Adrian Gheorghe Hasegan
Background/Objectives: Blood-count inflammatory indices may mark aggressive renal cell carcinoma (RCC), but their association with adverse pathology may reflect tumour size, anaemia or C-reactive protein (CRP). Methods: In a retrospective cohort of patients undergoing nephrectomy for RCC (2016–2025), five preoperative indices were related to pT3–4 stage and grade 3–4 in models fitted in the same patients, with adjustment for haemoglobin, tumour size (spline) and CRP, multiple imputation and assessment of incremental value. Results: Of 256 patients, 55/232 had pT3–4 and 71/235 grade 3–4 tumours. Per 1-SD increase in log systemic immune-inflammation index (SII), the odds ratio for pT3–4 was 2.21 (1.41–3.47) after adjustment for haemoglobin and size, 2.01 (1.07–3.76) with CRP added (137 patients) and 1.97 (1.27–3.05) after imputation. Adding SII to a model with tumour size increased the optimism-corrected AUC from 0.75 to 0.78. No leucocyte-based index was associated with grade after adjustment for haemoglobin. Conclusions: SII was associated with locally advanced RCC independently of tumour size, haemoglobin and CRP, but added little discrimination once tumour size was known. Validation against radiological staging is required.